Last update 21 Nov 2024

Chidamide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Tucidinostat
+ [9]
Target
Mechanism
HDAC inhibitors(Histone deacetylase inhibitors)
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CN (23 Dec 2014),
RegulationConditional marketing approval (CN), Special Review Project (CN), Orphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN)
Login to view timeline

Structure

Molecular FormulaC22H19FN4O2
InChIKeySZMJVTADHFNAIS-BJMVGYQFSA-N
CAS Registry1616493-44-7

External Link

KEGGWikiATCDrug Bank
-Chidamide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diffuse Large B-Cell Lymphoma
CN
24 Apr 2024
Adult T-Cell Leukemia-Lymphoma
JP
23 Jun 2021
Breast Cancer
CN
20 Nov 2019
Peripheral T-Cell Lymphoma
CN
23 Dec 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic melanomaPhase 3
IT
12 Aug 2021
Metastatic melanomaPhase 3
CZ
12 Aug 2021
Metastatic melanomaPhase 3
IT
12 Aug 2021
Metastatic melanomaPhase 3
AT
12 Aug 2021
Metastatic melanomaPhase 3
AU
12 Aug 2021
Metastatic melanomaPhase 3
AU
12 Aug 2021
Metastatic melanomaPhase 3
ZA
12 Aug 2021
Metastatic melanomaPhase 3
NZ
12 Aug 2021
Advanced breast cancerDiscovery
CN
01 Jul 2015
Hormone receptor positive breast cancerDiscovery
CN
01 Jul 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Hepatitis B
Maintenance
95
Chidamide maintenance therapy
apigbqfpwt(rnhfqfbcui) = neutropenia, anemia, thrombocytopenia xzuofsmijp (pdizbbzcgo )
Positive
09 Dec 2024
(Observation group)
Not Applicable
-
-
csvgqteihq(ayeyfczbbf) = one patient experienced grade 3/4 diarrhea jiynxhgege (rhdtdfvqbc )
-
07 Dec 2024
Phase 1/2
39
HBI-8000 + Nivolumab
(pwpenykxxc) = xmadfihtsn nqrsimqbqw (sdlcqmzcrh )
Positive
05 Nov 2024
Phase 2
23
(msvmgprkhu) = pvkzjdgxzl kdpkijdzku (ihlayswkoy, qfjqoeckhq - gteqycwjnu)
-
19 Sep 2024
Phase 2
43
Tucidinostat+capecitabine+aromatase inhibitors or fulvestrant
(dvdoxwoidc) = mivzizoimv rayafpxkml (sucsbqsapb )
Positive
16 Sep 2024
Phase 2
32
Envafolimab and chidamide in combination with GEMOX
(qmuxfhzvyt) = qdvyjaclpn phobqjaojb (dwbngzovew )
Positive
16 Sep 2024
Phase 1/2
21
(dpdbwphdjk) = zeskzxvgtu bayhxukutk (ecourqbdxk, 29.9 - 80.2)
Positive
15 Sep 2024
Not Applicable
66
Chidamide + CHOP(doxorubicin, cyclophosphamide, prednisone, and vincristine)
(cdufstmlll) = npcczrdjcc lfjmdygibs (vugxvsvcmi )
Positive
20 Aug 2024
CHOP(doxorubicin, cyclophosphamide, prednisone, and vincristine) alone
(cdufstmlll) = tqdaikvwis lfjmdygibs (vugxvsvcmi )
Phase 3
Diffuse Large B-Cell Lymphoma
First line
MYC expression | BCL2 expression
423
Tucidinostat plus R-CHOP
(zufgrysyob) = laddiyzamp brbrlczfnu (dhbvollszs, 48.9 - 67.6)
Positive
02 Jun 2024
Placebo plus R-CHOP
(zufgrysyob) = lwnbwfkqsw brbrlczfnu (dhbvollszs, 35.7 - 56.1)
Phase 2
85
(Autologous stem cell transplantation (ASCT))
(rgbqwwjcdy) = qvhsazowsu xelrrgnkad (ajmhwerknv )
Positive
28 May 2024
(rgbqwwjcdy) = qjrrjxalhi xelrrgnkad (ajmhwerknv )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free